Dali Pharmaceutical Co Ltd
Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection. The company's products include xingnaojing, shenmai, and astragalus injections, as well as citicoline injections. It also has patents, including invention patents and utility models. The company was founded in 1996 and is headquartered in Dali,… Read more
Dali Pharmaceutical Co Ltd (603963) - Net Assets
Latest net assets as of September 2024: CN¥361.39 Million CNY
Based on the latest financial reports, Dali Pharmaceutical Co Ltd (603963) has net assets worth CN¥361.39 Million CNY as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥450.20 Million) and total liabilities (CN¥88.81 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥361.39 Million |
| % of Total Assets | 80.27% |
| Annual Growth Rate | 7.88% |
| 5-Year Change | -18.5% |
| 10-Year Change | 40.89% |
| Growth Volatility | 38.02 |
Dali Pharmaceutical Co Ltd - Net Assets Trend (2012–2023)
This chart illustrates how Dali Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Dali Pharmaceutical Co Ltd (2012–2023)
The table below shows the annual net assets of Dali Pharmaceutical Co Ltd from 2012 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | CN¥381.12 Million | -4.99% |
| 2022-12-31 | CN¥401.16 Million | -4.23% |
| 2021-12-31 | CN¥418.86 Million | -11.04% |
| 2020-12-31 | CN¥470.85 Million | +0.69% |
| 2019-12-31 | CN¥467.62 Million | +0.75% |
| 2018-12-31 | CN¥464.13 Million | +0.15% |
| 2017-12-31 | CN¥463.43 Million | +118.62% |
| 2016-12-31 | CN¥211.98 Million | -12.16% |
| 2015-12-31 | CN¥241.31 Million | -10.80% |
| 2014-12-31 | CN¥270.52 Million | +5.06% |
| 2013-12-31 | CN¥257.48 Million | +55.62% |
| 2012-12-31 | CN¥165.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Dali Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 90.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥10.96 Million | 2.87% |
| Other Components | CN¥370.17 Million | 97.13% |
| Total Equity | CN¥381.12 Million | 100.00% |
Dali Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Dali Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arika Resources Ltd
AU:ARI
|
$10.22 Million |
|
Helios Energy Ltd
AU:HE8
|
$10.23 Million |
|
Kairous Acquisition Corp Ltd
NASDAQ:KACL
|
$10.23 Million |
|
RIV Capital Inc
PINK:CNPOF
|
$10.23 Million |
|
Innosimulation Co., Ltd
KQ:274400
|
$10.22 Million |
|
Dunia Virtual Online Tbk Pt
JK:AREA
|
$10.22 Million |
|
Agillic A/S
CO:AGILC
|
$10.22 Million |
|
Santa Fe Minerals Ltd
AU:SFM
|
$10.22 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Dali Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 401,156,357 to 381,124,985, a change of -20,031,372 (-5.0%).
- Net loss of 20,031,372 reduced equity.
- Dividend payments of 1,636,787 reduced retained earnings.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-20.03 Million | -5.26% |
| Dividends Paid | CN¥1.64 Million | -0.43% |
| Other Changes | CN¥1.64 Million | +0.43% |
| Total Change | CN¥- | -4.99% |
Book Value vs Market Value Analysis
This analysis compares Dali Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.68x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.56x to 0.68x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥2.11 | CN¥1.18 | x |
| 2018-12-31 | CN¥2.11 | CN¥1.18 | x |
| 2019-12-31 | CN¥2.13 | CN¥1.18 | x |
| 2020-12-31 | CN¥2.14 | CN¥1.18 | x |
| 2021-12-31 | CN¥1.91 | CN¥1.18 | x |
| 2022-12-31 | CN¥1.83 | CN¥1.18 | x |
| 2023-12-31 | CN¥1.73 | CN¥1.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Dali Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -5.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -22.95%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.24x
- Recent ROE (-5.26%) is below the historical average (3.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 29.33% | 22.54% | 0.95x | 1.37x | CN¥40.97 Million |
| 2017 | 9.59% | 16.30% | 0.45x | 1.32x | CN¥-1.89 Million |
| 2018 | 2.31% | 2.67% | 0.68x | 1.28x | CN¥-35.71 Million |
| 2019 | 2.89% | 4.59% | 0.52x | 1.20x | CN¥-33.26 Million |
| 2020 | 0.69% | 1.51% | 0.37x | 1.23x | CN¥-43.85 Million |
| 2021 | -10.00% | -24.43% | 0.31x | 1.31x | CN¥-83.78 Million |
| 2022 | -4.41% | -13.38% | 0.26x | 1.26x | CN¥-57.82 Million |
| 2023 | -5.26% | -22.95% | 0.18x | 1.24x | CN¥-58.14 Million |
Industry Comparison
This section compares Dali Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Dali Pharmaceutical Co Ltd (603963) | CN¥361.39 Million | 29.33% | 0.25x | $10.22 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |